Investor Presentation - First Six Months of 2021

119 Investor presentation First six months of 2021 Solid operating profit growth driven by Diabetes care Operating profit DKK billion 60 50 40 30 60% 50% 40% 30% 20 20 4% 1% -4% 11% 3% 20% 72% 10 6% 5% 3% 6% 7% 10% 0 0% 2016 2017 2018 2019 2020 Operating profit Operating profit as % of sales Reported operating profit growth Operating profit growth at CER *CER: Constant exchange rates Operating profit split per franchise 28% 81% 2016 2020 Diabetes and Obesity care Biopharm 19% Novo NordiskⓇ

View entire presentation